BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ... [Yahoo! Finance]
BioAtla, Inc. (BCAB)
Company Research
Source: Yahoo! Finance
For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points BioAtla Inc ( NASDAQ:BCAB ) is in advanced stages of finalizing a strategic transaction with a potential partner by year-end. The company achieved FDA alignment on the phase three OSV registrational trial design for treating second-line plus oropharyngeal squamous cell carcinoma (OPSCC). BioAtla Inc ( NASDAQ:BCAB ) presented compelling data from multiple programs, validating the potential of their CAB platform for treating difficult cancers. A development milestone was achieved under a license agreement with Context Therapeutics, providing non-dilutive capital and validating the CAB T-cell engager platform. The company estimates worldwide peak sales of their product for OPSCC to be approximately $800 million, with the total market projected to reach $3 billion by 2032. Negative Points BioAtla Inc ( NASDAQ:BCAB ) reported a net loss of $15.8 million for t
Show less
Read more
Impact Snapshot
Event Time:
BCAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAB alerts
High impacting BioAtla, Inc. news events
Weekly update
A roundup of the hottest topics
BCAB
News
- BioAtla Enters into Agreements for up to $22.5 Million Flexible FinancingGlobeNewswire
- BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch [Seeking Alpha]Seeking Alpha
- BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue SarcomasGlobeNewswire
- BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025GlobeNewswire
BCAB
Earnings
- 11/13/25 - Beat
BCAB
Sec Filings
- 12/5/25 - Form DEF
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- BCAB's page on the SEC website